Compare Amylx Pharmaceuticals Inc (AMLX) vs Dolby Laboratories, Inc. (DLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Dolby Laboratories, Inc. — how do they compare? Amylx Pharmaceuticals Inc trades at $17.65 (market cap $1.98B), while Dolby Laboratories, Inc. trades at $50 (market cap $4.71B). The key difference: Dolby Laboratories, Inc. is far larger — about 2.4× Amylx Pharmaceuticals Inc's market cap, and Dolby Laboratories, Inc. pays a 2.83% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | DLB | |
|---|---|---|
Market Cap | $1.98B | $4.71B |
Sector | Health | Industrials |
52-Week High | $18.70 | $76.79 |
52-Week Low | $7.64 | $49.31 |
Enterprise Value | $1.70B | $4.17B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
DLB trades at $49.8, down 0.64% on the day, with a bearish technical outlook but strong fundamentals. Recent earnings beats, including Q1 2026 EPS of $1.37 versus $1.31 expected, highlight operational strength. The company maintains high gross margins of 87.44% and positive cash flow, supported by licensing growth and expanding Dolby Atmos adoption.
The stock presents a value opportunity with a P/E of 19.76 below historical averages, and a consensus price target of $87.50 implies significant upside. Risks include cyclical end-market exposure and potential dilution from pipeline developments. Analyst sentiment is moderately bullish, but technical indicators suggest near-term pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →
